clinical trial · NCT07066657
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Locally Advanced or Metastatic Solid TumorsColorectal CancerGastric CancerPancreatic CancerMRG007
brief summary
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
started
Jul 25, 2025
primary completion
May 1, 2029
completion
Dec 1, 2030
last updated
Jun 4, 2026
official title
An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol